MRSN Earnings

MRSN reported its FY2025Q3 earnings on 2025-11-14, showcasing a revenue of 11.00M against an estimate of 14.00M, resulting in a -22.49% surprise. The EPS was 0, surpassing the expected -1.44 by 0% . The stock experienced a 1.79% price change on the earnings day and a 0.66% change over the next five days, reflecting market reactions to the results.

Following MRSN's FY2025Q3 earnings announcement on 2025-11-14, the stock price moved by 1.79% on the day of the release. Over the subsequent five days, it saw a 0.66% change. Historically, MRSN's stock price tends to shift by an average of +18.76% in the 10 days leading up to earnings and +6.58% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate MRSN’s annual revenue to reach 5.00M, while the EPS is projected at -3.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -8.78% and EPS estimates Revise Downward by -6.37% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between MRSN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -8.78%, while EPS estimates moved Revise Downward by -6.37% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, MRSN's stock price typically moves by +18.76% in the 10 days before its earnings and +6.58% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -3.00 and revenue of 5.00M.

The earnings call presents mixed signals. While there are positive signs such as increased collaboration revenue and reduced expenses, the unchanged net loss and restructuring charges raise concerns. The Q&A reveals uncertainties about clinical trial benchmarks and management's reluctance to provide specifics, which could worry investors. Despite some positive developments like strategic focus and cash runway extension, the lack of clear guidance and unresolved issues in clinical trials suggest a neutral market reaction.